Are you heading to the J.P. Morgan Healthcare Conference in January 2026? It’s the premier stage to showcase your vision, connect with investors, and tell your company’s story with confidence.
But to make every conversation count, you need more than a good pitch — you need a clear, credible commercialization plan that ties your strategy, milestones, and value together.
That’s where Corval Compass comes in.
Built specifically for early- and mid-stage biopharma teams, Corval Compass delivers a fast, affordable, and data-driven overview of your asset’s value and journey — without the complexity of a subscription-based software platform. In just days, you’ll receive a discussion-ready summary that helps you clarify your strategy, strengthen your investor narrative, and walk into every JPM meeting prepared.
WATCH NOW
In today’s tight funding environment, biopharma leaders don’t just need a compelling science story — they need a clear financial narrative that investors can trust.
If you’re a US-based biopharma company with a drug or biologic in Phase 2 or 3, we’re here to get you ready for JPM 2026! With Corval Compass, you can achieve rapid readiness and walk into investor meetings prepared. In just days — not weeks — you’ll receive a strategic snapshot of your asset’s commercial and launch plan, perfectly timed for JPM 2026 preparation. The deliverable provides discussion-ready insights that help you present a credible, data-backed story to investors, partners, and collaborators with confidence. Designed for early-stage biopharma teams, Corval Compass delivers affordable clarity — a low-lift, high-value way to align your team and make every major conversation count.
Click through a small selection of sample pages below.
Summarize your strategy. Strengthen your story. Be ready for JPM 2026.
👉 Learn more about Corval Compass